Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Equity Average (2016 - 2025)

Ptc Therapeutics has reported Equity Average over the past 13 years, most recently at -$180.5 million for Q4 2025.

  • Quarterly results put Equity Average at -$180.5 million for Q4 2025, up 83.22% from a year ago — trailing twelve months through Dec 2025 was -$180.5 million (up 83.22% YoY), and the annual figure for FY2025 was -$651.7 million, up 32.0%.
  • Equity Average for Q4 2025 was -$180.5 million at Ptc Therapeutics, roughly flat from -$181.2 million in the prior quarter.
  • Over the last five years, Equity Average for PTCT hit a ceiling of $387.3 million in Q1 2021 and a floor of -$1.1 billion in Q4 2024.
  • Median Equity Average over the past 5 years was -$245.8 million (2022), compared with a mean of -$360.7 million.
  • Biggest five-year swings in Equity Average: crashed 802.65% in 2023 and later soared 83.22% in 2025.
  • Ptc Therapeutics' Equity Average stood at $53.2 million in 2021, then tumbled by 639.65% to -$287.0 million in 2022, then plummeted by 159.48% to -$744.7 million in 2023, then plummeted by 44.52% to -$1.1 billion in 2024, then soared by 83.22% to -$180.5 million in 2025.
  • The last three reported values for Equity Average were -$180.5 million (Q4 2025), -$181.2 million (Q3 2025), and -$196.2 million (Q2 2025) per Business Quant data.